Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

NCT01718158 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

444

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

BIOLOGICAL: Peginterferon Lambda-1a
BIOLOGICAL: Peginterferon Alfa-2a
DRUG: Ribavirin
DRUG: Daclatasvir
DRUG: Telaprevir

Sponsor

Bristol-Myers Squibb